

- 1 - - C07D487/04+209B+209B+3



Office européen des brevets



(11) Publication number:

0 484 573 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90121267.0

(51) Int. Cl.⁵ C07D 487/04, C07D 209/34, A61K 31/40, //(C07D487/04, 209:00,209:00)

(22) Date of filing: 07.11.90

The application is published incomplete as filed (Article 93 (2) EPC). The point in the description at which the omission obviously occurs has been left blank.

(23) Date of publication of application: 13.05.92 Bulletin 92/20

(24) Designated Contracting States: AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED Route 202-206 North Somerville New Jersey 08876(US)


(72) Inventor: Glamkowski, Edward J. 7 Owens Drive Warren, NJ 07060(US) Inventor: Kurys, Barbara E. 69 Fencsak Avenue Elmwood Park, NJ 07407(US)

(74) Representative: Becker, Heinrich Karl Engelbert, Dr. et al HOECHST AKTIENGESELLSCHAFT Central Patent Department P.O. Box 80 03 20 W-6230 Frankfurt am Main 80(DE)

(54) 4- and 6-Carbamates related to physostigmine, a process and intermediates for their preparation and their use as medicaments.

(57) This invention relates to 4- and 6-carbamates related to physostigmine of the formula

REPLACED SHEETS	SG
☒ Description : paged to paged 21.....	
☒ Claim(s) : paged 21..... to paged 24.....	
☐ Drawing(s) : paged to paged 1.....	
☒ Abstract : paged 14..... to paged 1.....	
DATE OF RECEIPT	



SG 9608874-5

logged on 23/2/96

EP 0 484 573 A1

where R₁ is alkyl, cycloalkyl, bicycloalkyl, aryl or arylloweralkyl; R₂ is hydrogen or alkyl or the group -NR₁R₂ taken together forms a monocyclic or bicyclic ring of 5 to 12 carbons; m is 0, 1, or 2; each X is independently hydrogen, halogen, loweralkyl, nitro or amino; and the pharmaceutically acceptable acid addition salts thereof, and where applicable, the geometric and optical isomers and racemic mixtures thereof. This invention also relates to a process and intermediates for the preparation of the 4- and 6-carbamates. The compounds of this invention display utility for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease.

